DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for variant Creutzfeldt-Jakob disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleVariant Creutzfeldt-Jakob disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for variant creutzfeldt-jakob disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
prion protein (Kanno blood group) (PRNP) — PRNP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6LNI · 2.702 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No treatment is available for Creutzfeldt-Jakob disease or any transmissible subacute spongiform encephalopathy, according to a 1997 review. A few drugs had been shown to delay the onset of experimental disease in animals, but no human therapy existed at that time. The emergence of variant CJD in young people, possibly linked to bovine spongiform encephalopathy, prompted renewed research into therapeutic strategies, but no effective treatment has resulted from that effort.
A 2017 study of a mother and son in Spain with variant CJD found that the prion strain in both patients was identical to the UK reference strain, despite differences in age at onset and clinical presentation. The authors concluded that a single strain of agent appears responsible for all variant CJD cases to date. A 2021 report described a family with the D178N mutation in the PRNP gene causing familial CJD, noting phenotypic variability and anticipation — earlier onset in successive generations — but offered no therapeutic intervention.
A 2024 case report from Pakistan noted that CJD is reported in 1 in a million people per year worldwide, with only 12 cases recorded over 21 years (1994–2015) at Agha Khan Hospital in Karachi. The patient described had a delayed diagnosis and rapidly worsening symptoms. The report did not describe any treatment.
What remains missing is any clinical trial of a drug that slows or stops the disease in humans, adequate funding for such trials, and a reliable method for early diagnosis that would allow treatment before extensive neuronal loss. Patient stratification by prion strain or PRNP mutation type has not been tested in a therapeutic context.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Similarities of Variant Creutzfeldt-Jakob Disease Strain in Mother and Son in Spain to UK Reference Case
AbstractWe investigated transmission characteristics of variant Creutzfeldt-Jakob disease in a mother and son from Spain. Despite differences in patient age and disease manifestations, we found the same strain properties in these patients as in UK vCJD cases. A single strain of agent appears to be responsible for all vCJD cases to date.
Phenotypic Variability and Anticipation in a Family of D178N-Familial Creutzfeldt-Jakob Disease
AbstractFamilial Creutzfeldt-Jakob disease (fCJD) is caused by mutation in PRNP gene. The D178N variant of CJD is known to have phenotypic variability and can often mimic other neurological disorders. In this article, we report a family with D178N variant of PRNP mutation with phenotypic variability and anticipation phenomenon.
Expert Opinion on Investigational Drugs · 1997 · 1 citations · open access
Creutzfeldt-Jakob disease: therapeutic strategies
AbstractCreutzfeldt-Jakob disease (CJD) is a rare neurodegenerative illness which belongs to the group of transmissible subacute spongiform encephalopathies (TSSE). Today, no treatment is available for TSSE. The appearance of a new variant of CJD, which affects young people and could be linked to so-called ;mad cow disease', has stimulated researchers to develop new therapies against CJD. A few drugs have already been shown to delay the onset of experimental TSSE. They could contribute to the understanding of the pathogenic mechanisms involved in TSSE and, therefore, could be the basis for therapeutic strategies against CJD.
Journal of Islamic International Medical College · 2024 · 0 citations · open access
Unveiling a Diagnostic Odyssey: A Case Report on Delayed Diagnosis of Creutzfeldt Jakob Disease
AbstractCreutzfeldt Jakob Disease (CJD) is a rare prion infection causing rapid, progressive, invariably fatal neurodegenerative disorder. It is reported in 1 in a million people per year worldwide and only 12 cases have been reported over 21 years between 1994 to 2015 in Pakistan as per Agha Khan Hospital Karachi records. We are reporting the clinical course of such a patient with delayed diagnosis and rapidly worsening symptoms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
